AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: CNBC

What happened

Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.

Key facts

  • Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
  • Reported by CNBC and published Mon, 05 Oct 2026 19:44:30 UTC.

Why it matters

Economic releases and corporate results feed directly into rate expectations, currency moves and equity pricing, so the detail here often matters more to markets than the headline itself.

What to watch next

  • Revisions to the initial figures once fuller data is released
  • How rate expectations and index futures respond
  • Guidance or commentary from the companies and policymakers involved

Coverage timeline

When each newsroom published on this story, oldest first — all times UTC.

  1. Sainsbury’s and Morrisons ‘held talks this year’ on multibillion-pound merger

  2. Nvidia-backed Reflection AI unveils its first open model, Beam. Could it be America’s best chance to compete with China?

  3. AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment

Sources

The original report was published by CNBC. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at CNBC

Related WorldPing coverage